Novavax (NASDAQ: NVAX) director receives new equity awards as RSUs convert to shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Novavax director David M. Mott reported equity compensation and an RSU vesting event. On June 18, 2026, he received grants of 14,180 Restricted Stock Units and a stock option for 21,270 shares of common stock with a $9.13 exercise price. Both awards vest 100% on the first anniversary of the grant date, subject to his continued service on the Board.
On June 20, 2026, 18,880 previously granted RSUs fully vested and were converted into 18,880 shares of Novavax common stock. Following this conversion, he directly holds 79,770 shares of common stock. These transactions reflect compensation-related awards and an option-style RSU conversion, with no open-market buying or selling.
Positive
- None.
Negative
- None.
Insider Trade Summary
18,880 shares exercised/converted
Mixed
4 txns
Insider
MOTT DAVID M
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 18,880 | $0.00 | -- |
| Exercise | Common Stock | 18,880 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 21,270 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 14,180 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct, null);
Common Stock — 79,770 shares (Direct, null);
Stock Option (Right to Buy) — 21,270 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Key Figures
RSU grant: 14,180 units
Stock option grant: 21,270 shares
Option exercise price: $9.13 per share
+3 more
6 metrics
RSU grant
14,180 units
Restricted Stock Units granted on June 18, 2026
Stock option grant
21,270 shares
Option on common stock granted on June 18, 2026
Option exercise price
$9.13 per share
Exercise price for 21,270-share stock option
Option expiration
June 18, 2036
Expiration date of new stock option grant
RSUs converted
18,880 units
RSUs vested and converted to common stock on June 20, 2026
Common shares held
79,770 shares
Direct Novavax common stock holdings after RSU conversion
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), Amended and Restated 2015 Stock Incentive Plan, vesting
4 terms
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) for 21,270 underlying shares of Common Stock"
Amended and Restated 2015 Stock Incentive Plan financial
"option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest"
vesting financial
"One hundred percent (100%) of the RSUs subject to this grant will vest on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did Novavax (NVAX) director David M. Mott receive?
David M. Mott received a grant of 14,180 Restricted Stock Units and a stock option covering 21,270 shares. Both awards were granted at a zero grant price as part of Novavax’s Amended and Restated 2015 Stock Incentive Plan.
What is the exercise price and term of David M. Mott’s new Novavax stock options?
Mott’s new stock option covers 21,270 Novavax common shares at an exercise price of $9.13 per share. The option expires on June 18, 2036, providing a long-dated equity incentive tied to the company’s future stock performance.
When do David M. Mott’s recent Novavax equity awards vest?
Both the 14,180 RSUs and the stock option for 21,270 shares vest 100% on the first anniversary of the June 18, 2026 grant date. Vesting requires continued service on Novavax’s Board of Directors through that vesting date.
What happened to David M. Mott’s previously granted Novavax RSUs?
On June 20, 2026, 18,880 previously granted RSUs fully vested and converted into 18,880 Novavax common shares. After this conversion, Mott’s RSU balance from that grant dropped to zero, and his direct common stock holdings increased accordingly.
Do David M. Mott’s Form 4 transactions in Novavax involve open-market buying or selling?
The reported transactions consist of equity grants and an RSU conversion into common shares, with no open-market purchases or sales. The codes show derivative exercises and awards, indicating compensation-related activity rather than discretionary trading in Novavax stock.